Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 8/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11920854 | 0.83 | KMT2A (0.46) | MEN1KMT2ATGFBR1KDM4CNPC1 | |
| SCHEMBL7456661 | 0.71 | L3MBTL1 (0.42) | MEN1KMT2ATGFBR1KDM4CNPC1 | |
| SCHEMBL24553986 | 0.70 | MEN1 (0.47) | MEN1KMT2ATGFBR1KDM4CNPC1 | |
| SCHEMBL23703927 | 0.70 | KDM4C (0.51) | MEN1KMT2ATGFBR1KDM4CNPC1 | |
| SCHEMBL7460409 | 0.69 | MEN1 (0.46) | MEN1KMT2ATGFBR1KDM4CNPC1 | |
| SCHEMBL23116096 | 0.69 | MEN1 (0.44) | MEN1KMT2ATGFBR1KDM4CNPC1 | |
| SCHEMBL11024894 | 0.69 | MEN1 (0.54) | MEN1KMT2ATGFBR1KDM4CNPC1 | |
| SCHEMBL29832042 | 0.69 | TGFBR1 (0.56) | MEN1KMT2ATGFBR1KDM4CNPC1 | |
| SCHEMBL15597366 | 0.69 | CA12 (0.42) | MEN1KMT2ATGFBR1KDM4CNPC1 | |
| SCHEMBL5710973 | 0.69 | MEN1 (0.48) | MEN1KMT2ATGFBR1KDM4CNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | MEN1 914/4885KMT2A 2630/4885TGFBR1 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.